Halozyme Corporate Presentation 2022

Halozyme is a profitable biopharma company focused on its proprietary ENHANZE® drug delivery platform combined with autoinjector device technology. The company projects 2022 revenue of $655-685 million, representing 48-55% growth, driven by diverse revenue streams including partner collaborations and commercialized products.